Kura Oncology Inc. (NASDAQ:KURA) shares were down 3.1% on Monday . The stock traded as low as $4.89 and last traded at $5.00, with a volume of 189,643 shares changing hands. The stock had previously closed at $5.16.

Several research analysts have recently weighed in on KURA shares. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday.

The firm’s market capitalization is $99.15 million. The company has a 50-day moving average of $3.95 and a 200 day moving average of $3.64.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, equities analysts forecast that Kura Oncology Inc. will post ($1.72) EPS for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.